作者：
Paolo A,Ascierto [1]
;
Eleonora,Cioli [1]
;
Vanna,Chiarion-Sileni [2]
;
Pietro,Quaglino [3]
;
Francesco,Spagnolo [4]
;
Massimo,Guidoboni [5]
;
Michele,Del Vecchio [6]
;
Ketty,Peris [7]
;
Paola,Queirolo [4]
;
Luisa,Fioretto [8]
;
Corrado,Caracò [9]
;
Miriam,Paone [10]
;
Antonio,Sorrentino [1]
;
Mariaelena,Capone [1]
;
Diana,Giannarelli [1]
;
Gerardo,Ferrara [11]
;
Daniela,Massi [12]
;
Claudia,Trojaniello [13]
作者单位：
Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
[1]
Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
[2]
Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
[3]
Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
[4]
Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
[5]
Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
[6]
Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
[7]
Division of Melanoma Sarcoma and Rare Tumors, IEO European Institute of Oncology IRCCS Milan, Milan, Italy.
[8]
Medical Oncology Unit, Department of Oncology, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy.
[9]
Melanoma and Skin Cancers Surgery Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
[10]
Fondazione Policlinico Universitario A. Gemelli, IRCCS - Facility of Epidemiology & Biostatistics, Rome, Italy.
[11]
Department of Pathology and Cytopathology, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
[12]
Section of Pathology, Department of Health Sciences, University of Florence, Florence, Italy.
[13]
DOI
10.3389/fonc.2023.1107307
PMID
36845751
发布时间
2023-02-28
换一批
换一批
